المؤلفون: B.W.G. Van Rhijn, N. Van Dijk, L. Smit, K. Hendricksen, J.M. De Feijter, E. Bekers, A. Broeks, Y. Lubeck, K. Sikorska, T. Schumacher, P. Kvistborg, T. Boellaard, C.U. Blank, M.S. Van Der Heijden

المصدر: European Urology Open Science, Vol 19, Iss , Pp e2272- (2020)

مصطلحات موضوعية: Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666168320341410; https://doaj.org/toc/2666-1683

URL الوصول: https://doaj.org/article/5fa03bd074c9406cac10ee5288eb3ef2

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: van Dijk N; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Gil-Jimenez A; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., Silina K; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., van Montfoort ML; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Einerhand S; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Jonkman L; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, Netherlands., Voskuilen CS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Peters D; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, Netherlands., Sanders J; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Lubeck Y; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, Netherlands., Hooijberg E; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Vis DJ; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., van den Broek M; Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland., Wessels LFA; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands.; Department of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, Netherlands., van Rhijn BWG; Department of Urology, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany., van der Heijden MS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands.

المصدر: Frontiers in immunology [Front Immunol] 2021 Dec 20; Vol. 12, pp. 793964. Date of Electronic Publication: 2021 Dec 20 (Print Publication: 2021).

نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: CD8-Positive T-Lymphocytes/*immunology , Immune Checkpoint Inhibitors/*therapeutic use , Ipilimumab/*therapeutic use , Nivolumab/*therapeutic use , T-Lymphocytes, Helper-Inducer/*immunology , Urothelium/*metabolism, Aged ; CTLA-4 Antigen/antagonists & inhibitors ; Cell Differentiation ; Cells, Cultured ; Female ; Fluorescent Antibody Technique ; Forkhead Transcription Factors/metabolism ; Humans ; Immunotherapy ; Lymphocyte Activation ; Male ; Middle Aged ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism ; Tertiary Lymphoid Structures ; Treatment Outcome ; Tumor Microenvironment ; Urologic Neoplasms ; Urothelium/pathology